Enterome, Bristol-Myers Squibb Form Immuno-Oncology Alliance | GenomeWeb

NEW YORK (GenomeWeb) – Bristol-Myers Squibb has partnered with Enterome to discover and develop microbiome-derived biomarkers, drug targets, and bioactive molecules that may be used in the development of new cancer companion diagnostics and therapeutics, the companies announced today.

As part of the deal, the companies will also try to identify microbiome biomarkers that can be used to improve the clinical outcomes of patients treated with Bristol-Myers Squibb's immuno-oncology drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.